Compare · CSCI vs MRK
CSCI vs MRK
Side-by-side comparison of COSCIENS Biopharma Inc. (CSCI) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSCI and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $277.18B.
- MRK has hit the wire 23 times in the past 4 weeks while CSCI has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 0 for CSCI).
- Company
- COSCIENS Biopharma Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- -
- $277.18B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 23
- Recent ratings
- 0
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest CSCI
- COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
- COSCIENS Biopharma Inc. Announces Leadership Change
- COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- SEC Form 25 filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
Latest MRK
- EVP, Access, Policy & Comms Guindo Chirfi exercised 1,967 shares at a strike of $110.03 and covered exercise/tax liability with 969 shares, increasing direct ownership by 2% to 61,613 units (SEC Form 4)
- Exe V-P & Pres. MMD Chattopadhyay Sanat exercised 2,597 shares at a strike of $110.03 and covered exercise/tax liability with 1,130 shares, increasing direct ownership by 11% to 15,347 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 2,518 shares at a strike of $110.03 and covered exercise/tax liability with 1,241 shares, increasing direct ownership by 0.80% to 161,537 units (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 1,377 shares at a strike of $110.03 and covered exercise/tax liability with 679 shares, increasing direct ownership by 2% to 31,716 units (SEC Form 4)
- SVP Fin. - Global Controller Smart Dalton E. Iii exercised 1,408 shares at a strike of $110.33 and covered exercise/tax liability with 483 shares, increasing direct ownership by 11% to 9,137 units (SEC Form 4)
- Executive VP & President, MRL Li Dean Y covered exercise/tax liability with 2,326 shares and exercised 4,722 shares at a strike of $110.03, increasing direct ownership by 3% to 94,431 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 2,951 shares at a strike of $110.03 and covered exercise/tax liability with 1,454 shares, increasing direct ownership by 2% to 70,897 units (SEC Form 4)
- EVP, Chief HR Officer Larson Betty D exercised 13,435 shares at a strike of $110.81 and covered exercise/tax liability with 5,858 shares, increasing direct ownership by 122% to 13,774 units (SEC Form 4)
- EVP & CFO Litchfield Caroline exercised 3,935 shares at a strike of $110.03 and covered exercise/tax liability with 1,938 shares, increasing direct ownership by 2% to 92,301 units (SEC Form 4)
- Chairman, CEO & President Davis Robert M exercised 13,300 shares at a strike of $110.03 and covered exercise/tax liability with 6,551 shares, increasing direct ownership by 2% to 450,351 units (SEC Form 4)